Drugs / MK-6325
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT01329913 | May 2011 → Apr 2012 | hepatitis C virus infection | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MK-6325 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01329913 ↗ |
| Modality | Small molecule | — CHEMBL4297304 ↗ |
| Route | Oral | “Two 100 mg capsules, orally, once per day for 7 days” NCT01329913 ↗ |